BIO benefits from steady Clinical Diagnostics demand and international growth, but macro pressures and currency headwinds ...

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...

Ariel Investments, an investment management company, released its “Ariel Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here. Due to the economy’s resilience and ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The growth stock trade ...

With a market cap of $9.5 billion, Bio-Rad Laboratories, Inc. (BIO) operates in the healthcare and life sciences industry. The Hercules, California-based company develops and manufactures a wide range ...

Thank you for standing by. My name is Prila [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...

(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on August 27 and set a price target of $511.00. The company’s shares closed yesterday at $395 ...

Good afternoon everyone, and welcome to today's Bio-Rad First Quarter 2024 Earnings Results Conference Call. At this time, all lines are in a listen-only mode. Later, you will have the opportunity to ...